PubRank

N Pavlidis

Author PubWeight™ 128.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2013 2.53
2 Rectal metastases from lobular carcinoma of the breast: report of a case and literature review. Ann Oncol 2001 2.23
3 Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011 1.84
4 Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002 1.68
5 EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer 1996 1.58
6 Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013 1.52
7 Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 2010 1.40
8 Endometrioid carcinoma of the prostate. The diagnostic value of Leu7 and prostatic specific antigen. Br J Urol 1993 1.38
9 Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000 1.31
10 Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer 1994 1.30
11 Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003 1.24
12 Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 1.23
13 Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994 1.13
14 Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features. Lung Cancer 2004 1.12
15 ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2005 1.10
16 The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011 1.10
17 Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 2000 1.08
18 Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist 2001 1.07
19 Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000 1.06
20 Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time. Eur J Cancer 2003 1.02
21 ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 2005 1.00
22 Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology 1998 1.00
23 A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin. Anticancer Res 2008 0.99
24 Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994 0.99
25 Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol 2011 0.99
26 Cancer and pregnancy: a comprehensive review. Surg Oncol 2011 0.97
27 The missing kiss of life: transcriptional activity of the metastasis suppressor gene KiSS1 in early breast cancer. Anticancer Res 2007 0.96
28 Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009 0.96
29 Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma. Histol Histopathol 2004 0.96
30 ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2005 0.95
31 Primary extranodal non-Hodgkin's lymphoma of the head and neck. Oncology 1992 0.94
32 Thyroid disease in Sjögren's syndrome. Arthritis Rheum 1980 0.94
33 Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2001 0.94
34 Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2008 0.93
35 Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2000 0.93
36 Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer 2007 0.93
37 Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2008 0.93
38 Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010 0.92
39 Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2007 0.91
40 Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer 2013 0.90
41 Heterogeneity in cancer guidelines: should we eradicate or tolerate? Ann Oncol 2008 0.90
42 Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 1996 0.89
43 Renal cell carcinoma in pregnancy: a rare coexistence. Clin Transl Oncol 2013 0.89
44 Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Cancer Chemother Pharmacol 2012 0.89
45 Stress-induced impairment of macrophage tumoricidal function. Psychosom Med 1980 0.88
46 Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study. Oncology 1998 0.88
47 Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group. Br J Cancer 1996 0.88
48 Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. J Exp Clin Cancer Res 2004 0.88
49 Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol 2006 0.88
50 Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer 2006 0.88
51 Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol Oncol 1998 0.87
52 Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res 2006 0.87
53 Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer 2003 0.87
54 Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol 2000 0.87
55 Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemother Pharmacol 2011 0.86
56 Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res 2002 0.86
57 Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 2000 0.86
58 Clinical significance of low creatine phosphokinase values in patients with connective tissue diseases. JAMA 1981 0.85
59 Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. Eur J Cancer 2003 0.85
60 Correlative histologic and serologic findings of sicca syndrome in patients with systemic lupus erythematosus. Arthritis Rheum 1980 0.85
61 Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. J Cancer Res Clin Oncol 2007 0.85
62 Gastrointestinal, urologic and lung malignancies during pregnancy. Recent Results Cancer Res 2008 0.85
63 Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2006 0.84
64 Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1997 0.84
65 Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study. Clin Transl Oncol 2013 0.83
66 Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 1998 0.83
67 Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9. Anticancer Drugs 2001 0.83
68 Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx. Oral Oncol 2012 0.83
69 Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study. Eur J Cancer 1996 0.83
70 Juvenile cancer: improving care for adolescents and young adults within the frame of medical oncology. Ann Oncol 2005 0.83
71 Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study. Anticancer Res 2003 0.82
72 SESy-Europe: a multi-language database dedicated to cancer screening monitoring. J Exp Clin Cancer Res 2004 0.82
73 CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer J 2007 0.82
74 The treatment of cancer in Greek antiquity. Eur J Cancer 2004 0.82
75 Primary extranodal non Hodgkin's lymphoma of the head and neck in adults: a clinicopathological comparison between tonsillar and non tonsillar lymphomas. (Hellenic co-Operative Oncology Group). Anticancer Res 1999 0.82
76 Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. Br J Cancer 1996 0.82
77 Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group. Clin Exp Metastasis 2014 0.82
78 Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol 2001 0.82
79 Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009 0.82
80 Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999 0.82
81 Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 2003 0.82
82 Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008 0.81
83 Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid. Anticancer Res 1992 0.81
84 Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience. Oncology 2000 0.81
85 Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol Med 1999 0.81
86 Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 1996 0.81
87 Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2005 0.81
88 Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases. Acta Haematol 2005 0.81
89 Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol 2001 0.81
90 The influence of tamoxifen on serum triglycerides. Breast 2000 0.81
91 Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999 0.81
92 Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 1997 0.81
93 Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003 0.80
94 The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res 1996 0.80
95 Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol 2006 0.80
96 Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Res 2009 0.80
97 Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. Ann Oncol 2012 0.80
98 Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev 1983 0.80
99 Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer 1996 0.80
100 Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Oncology 2000 0.80
101 Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group. Semin Oncol 2000 0.80
102 ESMO Clinical Practice Guidelines: development, implementation and dissemination. Ann Oncol 2010 0.80
103 Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer. Eur J Cancer 1994 0.79
104 Oncology for medical students: a new ESO educational avenue. Ann Oncol 2005 0.79
105 ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer. Ann Oncol 2005 0.79
106 Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Med Pediatr Oncol 1996 0.79
107 Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. J Chemother 2003 0.79
108 Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. Eur J Haematol 2002 0.79
109 Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. Ann Oncol 2004 0.78
110 A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group study. Tumori 2000 0.78
111 Why is the topic of cancer and pregnancy so important? Why and how to read this book. Recent Results Cancer Res 2008 0.78
112 Megestrol activity in recurrent adult type granulosa cell tumour of the ovary. Ann Oncol 1997 0.78
113 Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. Cancer Chemother Pharmacol 2007 0.78
114 Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 2003 0.78
115 ESMO clinical recommendations: a practical guide for medical oncologists. Ann Oncol 2007 0.78
116 Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer. Lung Cancer 1999 0.78
117 High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study. Med Pediatr Oncol 1995 0.78
118 ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol 2005 0.78
119 Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature. Lung Cancer 2008 0.78
120 Fourteen years of evolution of ESMO Guidelines: from the minimum recommendations to the Consensus Conference-derived guidelines. Ann Oncol 2011 0.77
121 Levels of absolute survival benefit for systemic therapies of advanced cancer. a call for standards. Eur J Cancer 2003 0.77
122 p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study. Anticancer Res 1999 0.77
123 Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. Ann Oncol 2000 0.77
124 First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1998 0.77
125 A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 1997 0.77
126 Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study. Acta Oncol 1993 0.77
127 Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study. Ann Oncol 1997 0.77
128 Role of E-type prostaglandins in the regulation of interferon-treated macrophage cytotoxic activity. J Reticuloendothel Soc 1979 0.76
129 Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer Chemother Pharmacol 2007 0.76
130 Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study. Anticancer Res 2008 0.76
131 Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration 2000 0.76
132 Probing the unknown in cancer of unknown primary: which way is the right way? Ann Oncol 2010 0.76
133 Effect of intravenous nitroglycerin on lipid peroxidation after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1998 0.76
134 Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer 1997 0.76
135 Clear cell ovarian carcinoma in a pregnant woman with a history of infertility, endometriosis and unsuccessful IVF treatment. Eur J Gynaecol Oncol 2003 0.76
136 Local immune response after intravesical interferon gamma in superficial bladder cancer. Br J Urol 1998 0.76
137 Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999 0.76
138 G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 2001 0.76
139 New evidence that tamoxifen does not induce osteoporosis: a nuclear activation analysis and absorptiometry study. Br J Radiol 1992 0.75
140 Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. Am J Clin Oncol 2004 0.75
141 The effect of tamoxifen therapy on serum apolipoprotein A-I level is modified by the apolipoprotein E phenotype. Clin Biochem 2001 0.75
142 Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma. Am J Clin Oncol 1996 0.75
143 Immunomodulation in colorectal cancer: disappointment or promise? Ann Oncol 2003 0.75
144 Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Ann Oncol 2000 0.75
145 Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Invest New Drugs 2002 0.75
146 Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma. Oncology 1998 0.75
147 Undergraduate education in oncology in the Balkans and Middle East. The Metsovo Statement, April 4, 1997. Ann Oncol 1997 0.75
148 Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer. Semin Oncol 1997 0.75
149 Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study. Oncology 1998 0.75
150 Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. Chemotherapy 2005 0.75
151 Immunization of patients with Sjögren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. Arthritis Rheum 1980 0.75
152 Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group Study (HeCOG). J Exp Clin Cancer Res 1997 0.75
153 [An unusual case of follicular carcinoma of the thyroid]. Vopr Onkol 1989 0.75
154 Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study. Anticancer Drugs 2004 0.75
155 Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. Cancer Chemother Pharmacol 2005 0.75
156 Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen. Breast Cancer Res Treat 1996 0.75
157 Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin. J Exp Clin Cancer Res 1998 0.75
158 The ESMO guideline strategy: an identity statement and reflections on improvement. Ann Oncol 2015 0.75
159 Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007 0.75
160 A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer. Neoplasma 2010 0.75
161 Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer. Cancer Invest 2001 0.75
162 Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study. J Exp Clin Cancer Res 2001 0.75
163 Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective]. Anticancer Res 1998 0.75
164 Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group. Am J Clin Oncol 1999 0.75
165 Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer. Oncology 2001 0.75
166 Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Semin Oncol 1997 0.75
167 A phase-II study with idarubicin, etoposide and prednisone (IVPP), in patients with refractory or early relapsed intermediate or high grade non-Hodgkin's lymphoma. Haematologica 1999 0.75
168 ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of pancreatic cancer. Ann Oncol 2005 0.75
169 The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study. Lung Cancer 1994 0.75
170 ESMO Consensus Conferences: another source of ESMO Clinical Practice Guidelines. Ann Oncol 2012 0.75
171 Second malignancies following treatment for Hodgkin's disease: a Greek experience. Haematologica 1994 0.75
172 Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions. Ann Oncol 2000 0.75
173 A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group. Ann Oncol 1996 0.75
174 Docetaxel-induced enterocolitis: a serious and potentially fatal adverse event. J BUON 2012 0.75
175 Systemic dissemination in cancer of unknown primary is independent of mutational inactivation of the KiSS-1 metastasis-suppressor gene. Pathol Oncol Res 2008 0.75
176 Prognostic variables in greek patients with stage II breast cancer: a Hellenic Cooperative Oncology Group study. Anticancer Res 1998 0.75
177 Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases. Lung Cancer 2010 0.75
178 Prognostic factors influencing complete response to treatment and survival of patients with nasopharyngeal cancer. Anticancer Res 1998 0.75
179 Recurrent episodes of recall dermatitis of irradiated breast after LHRH agonist administration. J BUON 2011 0.75
180 Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. Oncology 2002 0.75
181 Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study. Oncology 1996 0.75
182 Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group. Ann Oncol 1994 0.75